In the article titled “Myricetin possesses potential protective effects on diabetic cardiomyopathy through inhibiting IκBα/NFκB and enhancing Nrf2/HO-1” [1], an error was identified in Figure 8(b) where the same original blots were mistakenly used for T-Nrf2 and HO-1 when preparing the image. The authors have provided the correct images for T-Nrf2 and HO-1 and the revised Figure 8 is as below:

(a)
(a)
(b)
(b)
(c)
(c)
(d)
(d)
(e)
(e)
Figure 8 
Myricetin regulated the expression of Nrf2 and HO-1 in neonatal rat cardiomyocytes (NRCM). (a) Myricetin enhanced the expression and nuclei translocation of Nrf2 after 36 h treatment with or without high glucose. (b) Representative blots showed the expression of Nrf2 and HO-1. (c–e) Histogram showed the fold change of T-Nrf2, Nuc-Nrf2, and HO-1; all of the proteins were normalized to GAPDH or histone 3 before relative quantitative analysis, and all experiments were repeated 3 times independently. Data were presented as . as compared with CON, and # as compared with HG group.